Assessment clinics at 'Avon Breast Screening Unit': what has changed in 5 years?

Abstract

Twenty-five years after its first description the p53 protein has been shown to play a key role in both cancer and ageing. The p53 protein is activated by many different stress pathways, including oncogene action and DNA damage. The elucidation of the p53 response, which is aberrant in most cancers (including breast, lung, stomach and colorectal cancer), has provided many new targets for drug development and p53 gene therapy is now approved in China. In tumours where p53 is mutant small molecules may be able to restore its function. In many tumours the wild-type p53 gene remains intact but its function is compromised by loss of upstream signalling pathways or downstream effectors.

Related Papers

• → Content of invitations for publicly funded screening mammography(2006)142 cited
• → Mammography Screening and Increased Incidence of Breast Cancer in Wisconsin(1991)44 cited
• Mammography screening among women aged 40-49 years shows no benefit.(2002)
• → Screening Mammography and Risk of Breast Cancer(1996)1 cited
• → Effects of organised mammography screening on breast cancer care in specialist breast units in Aachen, Germany since 2008(2020)